Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026)

Nuvectis Pharma has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 6050000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 6050000.0, down 13.47% year-over-year; the trailing twelve-month figure through Mar 2026 was 27160000.0 (down 34.72% YoY), and the FY2025 annual result was 26442000.0, down 39.17% from the prior year.
• Income from Continuing Operations came in at 6050000.0 for Q1 2026 at Nuvectis Pharma, up from 7314000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2943000.0 in Q1 2022 to a low of 7462000.0 in Q3 2025.
• The 5-year median for Income from Continuing Operations is 5877000.0 (2022), against an average of 5461000.0.
• Peak annual rise in Income from Continuing Operations reached 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
• Nuvectis Pharma's Income from Continuing Operations stood at 6696000.0 in 2022, then gained by 1.11% to 6622000.0 in 2023, then grew by 5.65% to 6248000.0 in 2024, then decreased by 17.06% to 7314000.0 in 2025, then increased by 17.28% to 6050000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 6050000.0 (Q1 2026), 7314000.0 (Q4 2025), and 7462000.0 (Q3 2025), per Business Quant data.